The registration of capmatinib and tepotinib MET inhibitors in Europe and the United States for NSCLC patients with MET exon 14 mutations has contributed to popularization of investigations of multiple genes, including MET gene, with the Next Generation Sequencing (NGS) technique using target sequencing or Comprehensive Genomic Profiling (CGP). This evidence concerns the gene MET and non-small cell lung carcinoma.